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doi:10.1016/j.kjms.2011.05.006Abstract Arsenic (As) is considered as a human carcinogen or tumor-promoting agent. Epide-
miological evidences indicated that cancer incidences of residents in arseniasis areas were
significantly higher in multiple organs, including urinary bladder, lungs, and especially the skin,
than those living in non-arseniasis areas. In the context of skin cancers, keratinocytes are
believed to be the main target cells in As carcinogenesis. Therefore, we discuss the signifi-
cance of keratinocyte-specific effects of As on skin carcinogenesis. As is known to be cytotoxic
because of its chemical reactions with the thiol group of proteins and its ability to generate
free radicals during cellular metabolism. However, at relatively low concentrations, As shows
stimulatory effects, such as cell activation and proliferation. Because long-term As exposure is
associated with skin carcinogenesis, we reviewed the mechanisms of As-induced keratinocyte
dysfunctions by means of time- and concentration-dependent cellular responses. The mecha-
nisms and interactions underlying As-induced keratinocyte dysfunctions not only provide
a model of As in skin carcinogenesis process but also help in understanding the regulation of
As carcinogenesis in other internal organs.
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.Introduction
Arsenic (As) remains to be one of the environmental toxi-
cants of greatest concern in the world. Because of theuan 1st Road, Kaohsiung 807,
.tw (H.-S. Yu).
vier Taiwan LLC. All rights reservnatural distribution of As in the crust of the earth, drinking
water is the most common source of As exposure for the
general population [1]. Apart from the well-known black-
foot disease in Taiwan, arsenical cancers have become the
most prominent health concerns. The International Agency
for Research on Cancer has classified As as a human
carcinogen [2]. Exposure to As in drinking water is almost
exclusively as inorganic As. The mode-of-action studies
suggest that As might act as a cocarcinogen, a promoter, or
a progressor of carcinogensis [3]. The World Healthed.
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limit of As concentration in groundwater [4]. Therefore,
many countries (including Taiwan, Japan, and the United
States) set 10 mg/L as the allowable limit of As concentra-
tion in drinking water. Long-term exposures to low-dosage
As may induce serious adverse health effects in multiple
organs. Chronic health effects of As exposure through
drinking water include skin and internal cancers, peripheral
vascular disease, ischemic heart disease, cerebral infarc-
tion, diabetes mellitus, and hypertension. Skin, lung,
urinary bladder, kidney, liver, and uterus are considered as
the sites related to As-induced malignancies [5,6]. Among
them, skin cancers have been well documented as an early
malignancy because of arsenical exposure [7e11]. Individ-
uals with documented epidermal keratinocyte malignancies
(such as Bowen’s disease) are considered for more aggres-
sive screening for long-term complications, especially for
the development of subsequent malignancies in the lungs
and urinary bladder system [12e15]. As skin is one of the
major organs for As carcinogenesis, the processes and
mechanisms responsible for As-induced keratinocyte
transformation are important issues for investigating As
carcinogenesis.As-induced thiol-group interaction and
reactive oxygen species generation in cells
As is a strong ligand to the thiol group (-SH) of proteins
[16e18]. This effect of As not only may compromise cell
signaling mediated by thiol proteins but also may affect the
cellular redox system mediated by glutathione [19]. Studies
on both As-induced skin lesions (such as Bowen’s disease,
an intraepidermal carcinoma) and As-treated keratinocytes
indicate that the increased 8-hydroxy-20-deoxyguanosine
DNA adduct (a typical oxidative DNA damage marker) levels
are positively correlated to the lesional As concentration
[20,21]. Because 8-hydroxy-20-deoxyguanosine is a typical
DNA adduct induced by oxidative stress, this finding
suggests the involvement of reactive oxygen species (ROS)
in As-induced DNA damage and genetic instability. As can
generate ROS during its biological metabolism process from
inorganic As to monomethylarsenic acid and dimethy-
larsinic acid [22,23] or its chemical reaction with nicotin-
amide adenine dinucleotide phosphate (NADPH) oxidase, an
enzyme involved in ROS generation [24,25]. In addition, As
is known to compromise cellular glutathione antioxidation
system through its binding with -SH groups. This function
can cause ROS accumulation in the cells [26]. As-induced
ROS is reported to be correlated with increased DNA
amplification, chromosome aberration, and sister chro-
matid exchange [27].Keratinocyte as a target cell for As
The As-induced ROS responses are tissue and cell type
specific. Under As treatments, human fibroblast cell line
(WI38) has higher antioxidative activities than human ker-
atinocyte cell line (HaCaT, an immortalized, non-
tumorigenic human keratinocyte cell line). In contrast,
keratinocytes have higher levels of ROS than fibroblastsunder As treatments [28]. These differences are believed to
depend on the basal level of redox genes (such as gluta-
thione reductase) and specific cellular responses [28,29].
These findings imply that, at least in part, keratinocytes are
one of the target cells that are sensitive to As-induced
oxidative stress and the related DNA damages.
Skin microenvironment under As exposure also provides
a carcinogenetic potential toward keratinocyte. Inflam-
mation (lymphocyte infiltration) is often observed in As-
induced lesions, such as As-induced Bowen’s disease (As-
BD) [30]. High concentrations of As induce human primary
keratinocyte apoptosis through Fas (also known as CD95)
and Fas ligand (FasL) pathway and induce circulatory or
peripheral T-helper cell (CD4þ) apoptosis through tumor
necrosis factor receptor-1/tumor necrosis factor-a pathway
[31,32]. However, at relatively low concentration (1 mM), As
induced soluble FasL expression without apoptosis induc-
tion in keratinocytes [31]. In contrast, As treatment was
found to induce Fas, but not FasL, expression on CD4þ cells
[32]. Therefore, the increased FasL expression by kerati-
nocytes in As-BD lesions generates an additional Fas/FasL
proapoptotic microenvironment to the infiltrating CD4þ
lymphocytes [33]. We propose that the additional kerati-
nocyte-anti-immune phenomenon present in the cutaneous
environment may contribute to the frequent occurrence of
As-induced cancers in the skin.Apoptosis by high concentrations of As in
keratinocytes
As (As2O3) is used to treat acute promyelocytic leukemia
(APL) because it induces apoptosis in leukemia cells [24]. As
is known to induce degradation of the PML-RAR fusion
protein (by genetic fusion of the retinoic acid receptor,
RAR, gene to the promyelocytic leukemia, PML, gene) in
APL cells [34]. PML-RAR is an important specific mediator of
the cellular sensitivity of As through its ability to induce
nicotinamide adenine dinucleotide phosphate oxidase
activation and to enhance ROS generation [35]. By means of
ROS, As induces APL cell apoptosis by Jun N-terminal kinase
(JNK)-associated activator protein 1 (AP-1) activation, p38
mitogen-activated protein kinase (MAPK)-associated B-cell
lymphoma 2/Bcl-2-associated X protein imbalance, and
nuclear factor kappa B (NF-kB)-associated dowregulation of
antiapoptotic FLICE-like inhibitory protein [24]. These
signals, in brief, result in cytochrome c release and acti-
vation of the mitochondria-associated caspase 9 cascade
[34]. This seems to be a common apoptotic mechanism in T
cell leukemia cells; multiple myeloma cells; and many solid
tumor cells (colonic, breast, pancreatic, and renal cell
carcinoma) [36].
In contrast, As-induced apoptosis in human keratino-
cytes is mediated by different mechanisms. In most of the
studies, greater than 1 mM of As induces keratinocyte
apoptosis relating to ROS generation or -SH binding. As-
induced ROS is associated with cellular DNA damage. The
tumor suppressor protein P53 is a key regulator in DNA
damage response, including cell cycle arrest and apoptosis.
As concentration dependently increases p53 expression in
keratinocytes and other types of cells [37,38]. However, in
keratinocytes, the As-induced (up to 10 mM) p53 expressions
Figure 1. Adverse effects of arsenic on keratinocyte prolif-
eration and apoptosis: a concentration-dependent model. AP-1
Z activator protein 1; MDM2 Z murine double minute; NF-kB
Z nuclear factor kappa B; ROSZ reactive oxygen species.
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bition of proliferation [39], instead of apoptosis. In
contrast, it has been identified that the transcription
factors Ets-like gene 1 (Elk-1) and AP-1 are associated with
keratinocyte apoptosis by high concentrations of As
(>1 mM). Through ROS, 10 mM of As activates MAPKs by
means of the downstream Elk-1 transcriptional control,
which stimulates RTP801 gene (also known as REDD1;
regulated in development and DNA damage responses 1)
transcription. This Elk-1-mediated RTP801 expression is
essential to mediate As-induced apoptosis in HaCaT kera-
tinocyte cell line [40]. Furthermore, high concentrations of
As induce JNK activation through binding with the -SH group
of JNK phosphatase, a negative regulator for JNK activity,
resulting in abnormal JNK activation [16]. This As-induced
JNK activation enhances the activity of transcription factor
AP-1 in human primary keratinocytes. The As-induced AP-1
activation further promotes Fas/FasL overexpression and
induces human primary keratinocyte apoptosis by the
downstream caspase 8 activation but not mitochondria-
associated caspase 9 activation [31]. In summary, through
ROS and -SH group binding, high concentrations of As
induces p53-associated cell cycle checking and AP-1-asso-
ciated Fas/FasL apoptotic pathway in keratinocytes.Cell survival by low concentrations of As in
kerationcytes
The chemical reactions (ROS generation and -SH binding)
are considered to be concentration dependently correlated
with As exposure. However, a certain research indicates
that As at low concentration has a protective effect against
oxidative stress and DNA damage in both fibroblasts and
keratinocytes [28]. This evidence may explain the
increased cell survival under low As concentrations.
Furthermore, differential activations of transcription
factors p53, AP-1, and NF-kB are involved at low As
concentration-induced keratinocyte abnormalities [16,41].
At low concentrations (1 mM), As not only induces p53
expression but also concomitantly increases the p53 inhib-
itory protein murine double minute (MDM2) [42,43]. Low
concentrations of As promote p53 nuclear export (p53
inactivation) through MAPK pathway and promoter-medi-
ated expression of human homologue of murine mdm2 in
keratinocytes. This functional loss of p53 in keratinocyte
results in impaired apoptosis in response to UV irradiation
or 5 flurouracil treatment [43]. These findings suggest that
a functional inhibition of As-induced p53 by low As
concentrations is able to compromise the normal functions
of keratinocytes against oxidative and genotoxic effects.
Low concentrations of As also increase cyclin D, cyclin-
dependent kinase 4, and adenovirus E2 gene promoter
region binding factor (E2F) expressions in keratinocytes;
persistent upregulation of these cell cycle regulatory
factors may lead to a loss of gap 1 phase to synthesis phase
cell cycle control [44,45]. Changes in NF-kB and AP-1
activities may also play important roles in As-induced cell
abnormalities. At low concentrations, As induced kerati-
nocyte proliferation and enhanced both NF-kB and AP-1
activities. At cytotoxic concentrations (>1 mM), NF-kB
activity was not enhanced; however, AP-1 activity wasfurther enhanced [31]. These results indicated that upre-
gulation of NF-kB at low As concentrations is related to
keratinocyte proliferation, which may be related to anti-
apoptotis signals of NF-kB [46] (Fig. 1). The effects of low-
concentration As on transcription factor AP-1 and NF-kB can
induce a series of abnormalities in cell functions. Among
them, the abnormalities in genes involved in growth regu-
lations are closely associated with As carcinogenesis. The
related factors that increased in As-treated keratinocytes
include transforming growth factor beta-b, granulocyte
macrophage colony-stimulating factor, interleukin-6, and
interleukin-8 [47e49]. These As-induced growth factors and
cytokines are reported to associate with As-induced cuta-
neous tumorigenesis by means of AP-1 and NF-kB tran-
scription regulation [50].
Keratinocyte transformation by long-term low-
concentration As exposure
Although the signals by low concentrations of As-exposed
keratinocytes are more closely correlated with carcino-
genesis than those by high As concentrations, data about
low-concentration As-induced cell transformation in short
term is still lacking. During the early carcinogenic trans-
formation stages, most of the cells acquire accumulation of
genetic instabilities and functional loss of cell checking,
such as p53-associated cell cycle arrest and apoptosis [51].
A 14-day low-concentration (0.1 mM) As treatment study
indicated that As increases poly adenosine-50-diphosphate-
ribosylation of P53 protein with decreased p21 expression
in HaCaT cells. Poly adenosine-50-diphosphate-ribosylation
of P53 protein is reported to block its active functioning as
a transcription factor. Therefore, within 14 days, As may
change the p53-associated cell cycleechecking mecha-
nisms, at least by decreasing the downstream p21 expres-
sion [52]. It is also reported that long-term low-
concentration As exposure can enhance cellular sensitivity
and response to epithelial growth factor [47,48], which can
further inhibit cell cycle inhibitory protein p27 expression
and cause cell hyperproliferation through myelocytoma-
tosis oncogene and E2F regulatory pathway [53]. For longer
As exposure period, it was identified that HaCaT cells
Figure 2. Possible mechanisms involved in keratinocytes under long-term low-concentration arsenic exposure. ADP Z adeno-
sine-50-diphosphate; c-myc Z myelocytomatosis oncogene; E2F Z adenovirus E2 gene promoter region binding factor; EGF Z
epidermal growth factor; PKB Z proteinkinase B.
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concentrations of arsenite, UVA irradiation, and chemo-
therapeutic compounds after being continuously exposed
to 0.1 mM of As for 28 weeks. Interestingly, these long-term-
treated HaCaT cells showed similar levels of UVA-induced
ROS and oxidative DNA damage compared with the control
cells [21]. Another study continuously exposed HaCaT cells
to 0.5 mM and 1 mM of As for 20 passages. These As-exposed
HaCaT cells become tumorigenic in nude mice, showing
resistance to As and increased frequency of micronuclei
[54]. The antiapoptotic effects in long-term low-concen-
tration-As-exposed HaCaT cells are related to decreased
p53 function [52], increased stability of nuclear protein
kinase B (a known antiapoptotic molecule) [21], increased
cellular glutathione levels (antioxidation) [54], and
survival/proliferation signals from epithelial growth factor
[47,48]. In addition, the tumorigenic HaCaT cells showed
loss of chromosome 9q (11 of 11; 100%) and gain of chro-
mosome 4q (9 of 11; 82%), indicating that As may induce
specific chromosomal alterations during tumorigenic
process of HaCaT keratinocytes [54] (Fig. 2).
Cells with these abnormal chromosomes are identified as
aneuploid. Aneuploidy frequently coincides with human
cancers relating to p53 mutation. Aneuploid DNA is also
observed in As-induced skin lesions, such as As-BD [55].
However, p53 mutation may not be a prerequisite in the
development of As-BD, because the mutation rate in As-BD
seems to vary among different human populations [56e58],
and in some As-BD populations, the p53mutation is quite low
[56]. Although p53 mutation may not be required for As-BD
formation, with p53 mutation, As-BD patients might be at
a higher risk of aneuploid phenotype and further invasive
transformation [59]. Although the mechanisms are not
clearly identified in keratinocytes, the association between
p53 and aneuploidy is studied in other types of cells. In lung
epithelial cells, we found that As induced centrosome
amplification, which implied an aneuploid event, in a p53
mutant cell line (H1355), but not in another cell line with
normal p53 (BEAS-2B) from the same organ source.When p53
activity of the normal cell line BEAS-2B got inhibited, As was
enabled to induce centrosome amplification in these cells
[37]. Therefore, exposure to chemicals or factors that
provide a p53-compromised status may increase the carci-
nogenetic risk of As. For example, As can act specifically on
the p53-compromised status induced by nicotine-derived
nitrosamine ketone, a tobacco smoke–specific compound,resulting in centrosomal abnormality and colony formation
[38]. These findings provide evidences on the carcinogenic
promotional role of arsenite under co-exposure with other
environmental factors.
Low concentrations of As increases NF-kB, E2F, and
growth factors associated with keratinocyte survival and
proliferation. Long-term low-concentration As exposure
induces additional dysfunctions in p53 regulation and growth
factor signaling. These As-induced abnormalities in kerati-
nocytes may cause cell survival with genomic defects by the
downregulated cell checking, that is, compromised p53.
Future perspective
More recently, epigenetic regulations have been noticed in
carcinogenesis. Epigenetic modifications by long-term low-
concentration As exposure are also an important mecha-
nism in As-induced cell transformation. Gene-specific
(promoter) hypermethylation associated with As exposure
is found in p53 promoter of human lung adenocarcinoma
cells [60], p16 promoter of human myeloma cells [61],
death-associated protein kinase promoter of human uroe-
pithelial cells [62,63], and deleted in bladder cancer
protein 1 promoter of human urothelial cells [64]. A global
DNA hypomethylation has been identified in HaCaT cells by
0.2 mM of As for 4 weeks; however, the gene-specific
epigenetic modifications in keratinocytes and its relation-
ship with skin carcinogenesis need further investigation
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